Company intelligence / Profile preview
Seldar Pharma
Bridgewater, New Jersey, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Seldar Pharma was established as a virtual company to develop and commercialize ASP7147, a GRPR antagonist originally from Astellas Pharma. The company's only known asset, ASP7147, reached Phase 2 clinical trials for irritable bowel syndrome with diarrhea. The study was completed but there is no public evidence of further development or additional pipeline assets.
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Astellas Pharma
Beyond the preview
Go deeper on Seldar Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seldar Pharma.